Morgan Stanley Reiterates “Overweight” Rating for Silence Therapeutics (NASDAQ:SLN)

Morgan Stanley reaffirmed their overweight rating on shares of Silence Therapeutics (NASDAQ:SLN) in a research report report published on Monday, Benzinga reports. Morgan Stanley currently has a $45.00 target price on the stock.

SLN has been the topic of a number of other research reports. HC Wainwright reaffirmed a buy rating and set a $75.00 price target on shares of Silence Therapeutics in a report on Friday, March 15th. BMO Capital Markets initiated coverage on Silence Therapeutics in a report on Wednesday, January 31st. They set an outperform rating and a $67.00 target price on the stock. Finally, Chardan Capital boosted their target price on Silence Therapeutics from $26.00 to $42.00 and gave the stock a buy rating in a report on Thursday, March 14th.

Silence Therapeutics Trading Down 2.9 %

Shares of NASDAQ SLN opened at $21.62 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.56 and a quick ratio of 4.56. The firm’s 50-day moving average price is $23.03 and its two-hundred day moving average price is $17.41. Silence Therapeutics has a 52-week low of $4.60 and a 52-week high of $27.72.

Silence Therapeutics (NASDAQ:SLN) last issued its earnings results on Wednesday, March 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.22). The business had revenue of $2.61 million during the quarter, compared to the consensus estimate of $11.46 million. Silence Therapeutics had a negative return on equity of 262.17% and a negative net margin of 171.41%. On average, research analysts predict that Silence Therapeutics will post -1.38 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SLN. Vivo Capital LLC grew its position in Silence Therapeutics by 116.7% during the 1st quarter. Vivo Capital LLC now owns 1,105,454 shares of the company’s stock worth $23,878,000 after purchasing an additional 595,250 shares in the last quarter. Parkman Healthcare Partners LLC grew its position in Silence Therapeutics by 20.8% during the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock worth $4,046,000 after purchasing an additional 40,063 shares in the last quarter. SG Americas Securities LLC purchased a new position in Silence Therapeutics during the 4th quarter worth approximately $110,000. Finally, Lynx1 Capital Management LP purchased a new position in Silence Therapeutics during the 3rd quarter worth approximately $2,315,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.